Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Leukemia

Volumn 26, Issue 5, 2012, Pages 893-901

  Pollyea, D A ^a   Kohrt, H E ^b   Gallegos, L ^b   Figueroa, M E ^c   Abdel Wahab, O ^d   Zhang, B ^b   Bhattacharya, S ^b   Zehnder, J ^b   Liedtke, M ^b   Gotlib, J R ^b   Coutre, S ^b   Berube, C ^b   Melnick, A ^e   Levine, R ^d   Mitchell, B S ^b   Medeiros, B C ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Elderly AML; methylation; phase one

Indexed keywords

AZACITIDINE; COLONY STIMULATING FACTOR 1; INTERLEUKIN 17; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTHRITIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER REGRESSION; CELLULITIS; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DNA METHYLATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEMOPTYSIS; HUMAN; HYPONATREMIA; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; COHORT STUDIES; CYTOKINES; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84860781677     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.294     Document Type: Article

References (37)

1. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179-4187.
2. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol 2008; 35: 430-438.
3. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
4. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982; 60: 309-315.
5. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
6. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108: 63-73.
7. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116: 4762-4770.
8. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2(Suppl 1): S4-11.
9. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007; 26: 6697-6714.
10. Issa JP. Aging, DNA methylation and cancer. Crit Rev Oncol Hematol 1999; 32: 31-43.
11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
12. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006; 107: 1839-1843.
13. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
14. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979.
15. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406-11411.
16. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116: 3227-3237.
17. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28: 4919-4925.
18. Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011; 117: 1828-1833.
19. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.
20. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010; 28: 2253-2258.
21. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925-937.
22. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD, 2006.
23. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
24. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
25. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
26. Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005; 19: 1479-1482.
27. Ahn JY, Seo K, Weinberg O, Boyd SD, Arber DA. A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. J Mol Diagn 2009; 11: 319-323.
28. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffinembedded glioma tissues. J Neuropathol Exp Neurol 2009; 68: 1319-1325.
29. Khulan B, Thompson RF, Ye K, Fazzari MJ, Suzuki M, Stasiek E et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006; 16: 1046-1055.
30. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
31. AML Score, Available at http://www.aml-score.org/(accessed 12 February 2011).
32. Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008.
33. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117: 2697-2702.
34. Sekeres MA, O'Keefe C, List AF, Paulic K, Afable II M, Englehaupt R et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol 2011; 86: 102-103.
35. Sekeres MA, List A. Immunomodulation in myelodysplastic syndromes. Best Pract Res Clin Haematol 2006; 19: 757-767.
36. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251-4261.
37. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004; 72: 89-106.